Science and Global Health R&D Fund — Generic Drug Repurposing
Funds late-stage clinical studies repurposing medicines for severe disease burdens in lower-income settings.
The Generic Drug Repurposing RFP is Coefficient Giving's global health R&D program for late-stage clinical trials that repurpose approved generic drugs for neglected diseases affecting low- and lower-middle-income countries. It sits under the Science and Global Health R&D Fund and is built around human clinical evidence rather than early discovery work. The call has up to $20 million available across proposals, with no per-project ceiling stated in the record. Applicants may be based anywhere, including institutions or individuals, but the therapy must target a new indication and benefit LMIC patients. Eligible projects need Phase IIc or Phase III trials that can finish within five years, and they must have IRB or ethics review capacity plus prior experience with human clinical research. Supportive evidence can come from preclinical data, observational studies, prior trials, or clinical observations. The best fit is a team that can present a serious clinical package with a clear burden-of-disease case and a realistic path to completion. Coefficient is looking for work that is executable, not exploratory, so the proposal needs strong evidence, sound governance, and a trial design that can move efficiently from concept to patient benefit.
Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.